Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Medical Devices

MiMedx Group, Inc. is an advanced wound care and an emerging therapeutic biologics company. The company is headquartered in Marietta, Georgia and currently employs 690 full-time employees. The firm`s Regenerative Biomaterials segment includes the design, manufacture, and marketing of products and tissue processing services for the Wound Care, Surgical, Sports Medicine, Ophthalmic and Dental market categories. Its biomaterial platform technologies include AmnioFix, EpiFix, OrthoFlo, Physio, AlloBurn, and CollaFix. AmnioFix and EpiFix are its tissue technologies processed from human amniotic membrane derived from donated placentas. OrthoFlo is amniotic fluid-derived allograft for homologous use. Physio is a bone grafting material consists of bone tissue with no added carrier. CollaFix, its new brand, is its collagen fiber technology designed to mimic the natural composition, structure and mechanical properties of musculoskeletal tissues in order to augment their repair.
Website: mimedx.com



Growth: Bad revenue growth rate -35.4%, there is slowdown compared to average historical growth rates 7.0%. The revenue growth dynamics is unstable

Profitability: LTM EBITDA margin is positive, +2.5%. On average the margin is decreasing unsteadily. In the last quarter the company beat the estimated EPS. The company was ahead of estimated EPS in 40% of quarters (showing a gain of $0 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield 5.5% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 5.1% higher than minimum and 66.0% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued 1.3x by EV / Sales multiple , the company can be 29.0% undervalued

Key Financials (Download financials)

Ticker: MDXG
Share price, USD:  (+0.3%)3.32
year average price 4.99  


year start price 7.54 2025-11-11

max close price 7.54 2025-11-11

min close price 3.16 2026-11-05

current price 3.32 2026-11-10
Common stocks: 147 795 741

Dividend Yield:  0.0%
FCF Yield LTM: 5.5%
EV / LTM EBITDA: 41.1x
EV / Sales: 1.0x
Margin (EBITDA LTM / Revenue): 2.5%
Fundamental value created in LTM:
Market Cap ($m): 489
Net Debt ($m): -119
EV (Enterprise Value): 370
Price to Book: 2.0x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2025-12-22globenewswire.com

MIMEDX Enters into Exclusive U.S. Distribution Agreement for RegenKit®-Wound Gel

2025-11-03globenewswire.com

MIMEDX Comments on CY 2026 Medicare Physician Fee Schedule Final Rule

2025-07-30seekingalpha.com

MiMedx Group, Inc. (MDXG) Q2 2025 Earnings Call Transcript

2025-07-30zacks.com

MiMedx (MDXG) Q2 Earnings and Revenues Beat Estimates

2025-07-15globenewswire.com

MIMEDX Comments on Proposed Medicare Reimbursement Rule Changes for CY 2026

2025-07-09zacks.com

Strength Seen in MiMedx (MDXG): Can Its 8.0% Jump Turn into More Strength?

2025-04-30seekingalpha.com

MiMedx Group, Inc. (MDXG) Q1 2025 Earnings Call Transcript

2025-04-30zacks.com

MiMedx (MDXG) Q1 Earnings Match Estimates

2025-02-26seekingalpha.com

MiMedx Group, Inc. (MDXG) Q4 2024 Earnings Call Transcript

2025-02-26zacks.com

MiMedx (MDXG) Q4 Earnings Meet Estimates
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol MDXG MDXG MDXG MDXG MDXG MDXG MDXG MDXG MDXG MDXG MDXG MDXG MDXG MDXG
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-10-29 2025-07-30 2024-10-30 2024-07-31 2024-04-30 2023-10-30 2023-08-01 2023-05-02 2022-11-02
acceptedDate 2025-10-29 16:00:50 2025-07-30 16:01:02 2025-02-26 16:00:35 2024-10-30 16:01:55 2024-07-31 16:00:39 2024-04-30 16:04:03 2024-02-28 16:02:35 2023-10-30 16:07:41 2023-08-01 16:04:50 2023-05-02 16:01:05 2023-05-01 16:36:20 2022-11-02 16:15:47 2022-02-28 17:11:13 2021-03-08 17:27:53
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
revenue 114M 99M 349M 84M 87M 85M 321M 82M 81M 72M 268M 68M 242M 248M
costOfRevenue 19M 19M 60M 15M 15M 13M 55M 15M 14M 12M 48M 12M 40M 39M
grossProfit 95M 80M 289M 69M 72M 72M 267M 67M 68M 59M 220M 56M 202M 209M
grossProfitRatio 0.835 0.811 0.818 0.827 0.844 0.819 0.833 0.827 0.82
researchAndDevelopmentExpenses 4M 3M 12M 3M 3M 3M 13M 3M 8M 6M 13M 6M 10M 12M
generalAndAdministrativeExpenses 0 16M 0 0 0 0 0 0 0 0 0 0 0 0
sellingAndMarketingExpenses 0 48M 0 0 0 0 0 0 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 69M 64M 216M 54M 55M 55M 216M 53M 52M 52M 221M 53M 195M 240M
otherExpenses 112 000 100 000 1M 1M 10M -311 000 762 000 -11 000 -32 000 4M 701 000 3M 5M 2M
operatingExpenses 73M 68M 230M 58M 49M 58M 230M 56M 62M 63M 234M 63M 209M 254M
costAndExpenses 92M 86M 290M 73M 64M 71M 284M 71M 75M 75M 283M 75M 249M 294M
interestIncome 0 1M 0 278 000 0 0 0 2M 2M 0 0 0 0 0
interestExpense 785 000 475 000 1M 0 3000 2M 6M 2M 2M -2M 5M 1M 5M 8M
depreciationAndAmortization 5M 3M 6M 773 000 767 000 747 000 3M 843 000 877 000 904 000 4M 886 000 5M 7M
ebitda 29M 16M 65M 12M 23M 14M 41M 12M 7M -2M -11M -6M -2M -38M
ebitdaratio 0.254 0.157 0.145 0.278 0.165 0.145 0.083 -0.035 -0.092
operatingIncome 22M 12M 59M 11M 23M 13M 37M 11M 3M -3M -15M -7M -7M -45M
operatingIncomeRatio 0.195 0.125 0.133 0.269 0.156 0.132 0.034 -0.047 -0.105
totalOtherIncomeExpensesNet 659 000 637 000 -2M 257 000 -234 000 -2M -6M -219 000 -3M -2M -5M -1M -5M -16M
incomeBeforeTax 23M 13M 57M 11M 23M 11M 31M 9M 1M -5M -20M -8M -12M -62M
incomeBeforeTaxRatio 0.201 0.132 0.136 0.266 0.135 0.112 0.014 -0.069 -0.124
incomeTaxExpense 6M 3M 15M 4M 6M 2M -37M 591 000 -74 000 51 000 206 000 53 000 247 000 -12M
netIncome 17M 10M 42M 8M 18M 9M 67M 7M 1M -5M -30M -8M -12M -49M
netIncomeRatio 0.147 0.098 0.096 0.202 0.109 0.083 0.015 -0.07 -0.124
eps 0.11 0.065 0.29 0.055 0.12 0.063 0.48 0.058 0.01 -0.044 -0.27 -0.074 -0.093 -0.46
epsdiluted 0.11 0.064 0.055 0.12 0.062 0.057 0.01 -0.044 -0.074
weightedAverageShsOut 148M 148M 147M 147M 147M 146M 116M 116M 116M 114M 113M 113M 110M 108M
weightedAverageShsOutDil 150M 149M 149M 148M 149M 150M 146M 119M 116M 114M 113M 113M 110M 108M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-26 2024-02-28 2023-05-01 2022-02-28 2021-03-08
fiscalYear 2024 2023 2022 2021 2020
netInterestIncome -1M -6M -5M -5M -8M
ebit 59M 37M -15M -7M -44M
nonOperatingIncomeExcludingInterest -446 000 0 0 23 000 -1M
netIncomeFromContinuingOperations 42M 67M -20M -12M -49M
netIncomeFromDiscontinuedOperations 421 000 0 -10M 0 0
otherAdjustmentsToNetIncome 0 0 0 0 0
netIncomeDeductions 0 0 0 0 0
bottomLineNetIncome 42M 56M -37M -18M -49M
epsDiluted 0.28 0.38 -0.27 -0.093 -0.46

Balance Sheet Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol MDXG MDXG MDXG MDXG MDXG MDXG MDXG MDXG MDXG MDXG MDXG MDXG MDXG MDXG
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-10-29 2025-07-30 2024-10-30 2024-07-31 2024-04-30 2023-10-30 2023-08-01 2023-05-02 2022-11-02
acceptedDate 2025-10-29 16:00:50 2025-07-30 16:01:02 2025-02-26 16:00:35 2024-10-30 16:01:55 2024-07-31 16:00:39 2024-04-30 16:04:03 2024-02-28 16:02:35 2023-10-30 16:07:41 2023-08-01 16:04:50 2023-05-02 16:01:05 2023-05-01 16:36:20 2022-11-02 16:15:47 2022-02-28 17:11:13 2021-03-08 17:27:53
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
cashAndCashEquivalents 142M 119M 104M 89M 69M 48M 82M 81M 69M 61M 66M 73M 87M 96M
shortTermInvestments 0 0 0 0 0 0 0 0 0 0 0 0 0 0
cashAndShortTermInvestments 142M 119M 104M 89M 69M 48M 82M 81M 69M 61M 66M 73M 87M 96M
netReceivables 78M 69M 56M 54M 53M 57M 54M 49M 49M 45M 43M 42M 40M 35M
inventory 27M 25M 24M 24M 25M 24M 21M 19M 17M 15M 13M 14M 11M 10M
otherCurrentAssets 7M 8M 3M 5M 7M 9M 2M 2M 3M 2M 5M 7M 4M 13M
totalCurrentAssets 254M 221M 192M 172M 154M 139M 164M 155M 141M 132M 134M 136M 149M 161M
propertyPlantEquipmentNet 10M 10M 12M 9M 10M 11M 9M 10M 10M 11M 11M 12M 14M 15M
goodwill 19M 19M 19M 19M 19M 19M 19M 19M 19M 20M 19M 20M 20M 20M
intangibleAssets 11M 12M 12M 11M 12M 13M 5M 5M 6M 6M 6M 5M 5M 6M
goodwillAndIntangibleAssets 31M 31M 31M 31M 31M 32M 25M 25M 25M 26M 25M 25M 25M 26M
longTermInvestments 0 0 0 0 -1 -39M 0 0 0 0 0 0 0 0
taxAssets 22M 27M 28M 31M 33M 39M 41M 0 0 0 0 0 0 0
otherNonCurrentAssets 3M 989 999 1M 1M 1M 40M 205 000 149 000 146 000 147 000 683 000 150 000 186 000 375 000
totalNonCurrentAssets 65M 70M 72M 72M 76M 83M 75M 35M 35M 36M 37M 37M 39M 41M
otherAssets 0 0 0 0 1 0 0 0 0 0 0 0 0 0
totalAssets 319M 291M 264M 244M 230M 222M 239M 189M 176M 168M 171M 173M 188M 202M
accountPayables 11M 8M 7M 7M 8M 10M 9M 9M 8M 8M 8M 9M 7M 9M
shortTermDebt 1M 1M 1 000 000 1 000 000 1 000 000 1 000 000 0 0 0 0 1M 0 0 0
taxPayables 0 0 0 0 0 0 0 0 0 0 0 0 0 0
deferredRevenue 0 0 0 0 0 0 0 0 0 0 0 0 0 0
otherCurrentLiabilities 45M 41M 25M 34M 31M 32M 15M 34M 36M 33M 13M 37M 4M 26M
totalCurrentLiabilities 58M 50M 46M 42M 40M 42M 46M 44M 44M 41M 44M 46M 42M 59M
longTermDebt 17M 17M 18M 18M 18M 18M 48M 49M 49M 49M 49M 48M 48M 48M
deferredRevenueNonCurrent 0 0 0 0 0 0 0 0 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 0 0 0 0 0 0 0 0 0
otherNonCurrentLiabilities 6M 7M 3M 3M 4M 5M 2M 95M 96M 97M 2M 45M 951 000 795 000
totalNonCurrentLiabilities 22M 24M 25M 21M 22M 24M 50M 144M 145M 145M 53M 54M 53M 51M
otherLiabilities 0 0 0 0 0 0 0 0 0 0 0 0 0 0
capitalLeaseObligations 0 0 6M 0 0 0 0 4M 0 0 2M 0 5M 4M
totalLiabilities 80M 74M 71M 63M 62M 66M 96M 188M 189M 186M 97M 100M 95M 111M
preferredStock 0 0 0 0 0 0 0 92M 92M 92M 92M 92M 92M 92M
commonStock 148 000 148 000 147 000 147 000 147 000 148 000 146 000 116 000 116 000 115 000 114 000 114 000 113 000 113 000
retainedEarnings -58M -75M -91M -99M -107M -124M -134M -187M -196M -197M -192M -191M -162M -151M
accumulatedOtherComprehensiveIncomeLoss 0 0 0 0 0 0 0 -92M -92M 0 0 0 0 -0
othertotalStockholdersEquity 297M 291M 280M 275M 280M 188M 183M 86M 172M
totalStockholdersEquity 239M 217M 193M 181M 168M 156M 143M 1M -13M -18M 75M 73M 93M 91M
totalEquity 239M 217M 193M 181M 168M 156M 143M 1M -13M -18M 75M 73M 93M 91M
totalLiabilitiesAndStockholdersEquity 319M 291M 244M 230M 222M 189M 176M 168M 173M
minorityInterest 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 319M 291M 264M 244M 230M 222M 239M 189M 176M 168M 171M 173M 188M 202M
totalInvestments 0 0 0 0 -1 -39M 0 0 0 0 0 0 0 0
totalDebt 18M 18M 25M 19M 19M 19M 48M 49M 49M 49M 52M 48M 53M 52M
netDebt -124M -100M -80M -70M -50M -29M -34M -32M -20M -13M -13M -25M -34M -44M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-26 2024-02-28 2023-05-01 2022-02-28 2021-03-08
fiscalYear 2024 2023 2022 2021 2020
accountsReceivables 56M 54M 43M 40M 35M
otherReceivables 0 0 0 0 0
prepaids 5M 6M 7M 6M 6M
totalPayables 9M 9M 8M 7M 9M
otherPayables 1M 0 0 0 0
accruedExpenses 9M 22M 21M 30M 23M
capitalLeaseObligationsCurrent 1M 0 0 1M 1M
capitalLeaseObligationsNonCurrent 5M 0 2M 4M 3M
treasuryStock 0 0 0 -4M -7M
additionalPaidInCapital 284M 276M 174M 166M 159M
otherTotalStockholdersEquity 0 0 0 -0 0

Cash Flow Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol MDXG MDXG MDXG MDXG MDXG MDXG MDXG MDXG MDXG MDXG MDXG MDXG MDXG MDXG
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-10-29 2025-07-30 2024-10-30 2024-07-31 2024-04-30 2023-10-30 2023-08-01 2023-05-02 2022-11-02
acceptedDate 2025-10-29 16:00:50 2025-07-30 16:01:02 2025-02-26 16:00:35 2024-10-30 16:01:55 2024-07-31 16:00:39 2024-04-30 16:04:03 2024-02-28 16:02:35 2023-10-30 16:07:41 2023-08-01 16:04:50 2023-05-02 16:01:05 2023-05-01 16:36:20 2022-11-02 16:15:47 2022-02-28 17:11:13 2021-03-08 17:27:53
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
netIncome 17M 10M 42M 8M 18M 9M 67M 9M 1M -5M -20M -8M -12M -49M
depreciationAndAmortization 5M 3M 6M 2M 767 000 747 000 3M 843 000 877 000 904 000 4M 1M 5M 7M
deferredIncomeTax 6M 287 000 12M 3M 5M 2M -38M 292 000 3M 0 0 0 0 0
stockBasedCompensation 5M 5M 17M 4M 4M 4M 17M 4M 4M 4M 0 2M 14M 15M
changeInWorkingCapital -6M -4M -5M 9M 2M -12M -18M -2M -2M -5M -8M 5M -19M -16M
accountsReceivables -11M -7M -3M -953 000 4M -3M -12M -489 000 -5M -2M -6M -4M -11M -3M
inventory -2M -820 000 -2M 807 000 -663 000 -3M -8M -2M -2M -1M -2M -593 000 -1M -1M
accountsPayables 3M -668 000 -1M -1M -1M 283 000 783 000 453 000 893 000 -1M 839 000 648 000 -159 000 177 000
otherWorkingCapital 4M 5M 885 000 10M 321 000 -6M 876 000 566 000 4M -683 000 -1M 9M -7M -12M
otherNonCashItems 3M 791 000 -6M -4M -5M 12M -5M 456 000 469 000 417 000 6M 887 000 10M 12M
netCashProvidedByOperatingActivities 29M 14M 66M 22M 22M 5M 27M 13M 8M -4M -18M 959 000 -2M -30M
investmentsInPropertyPlantAndEquipment -192 000 0 -2M 2M -419 000 -1M -2M -649 000 -348 000 -677 000 -3M -374 000 -3M -4M
acquisitionsNet 0 0 -8M 0 0 0 0 0 0 0 24 000 0 0 0
purchasesOfInvestments 0 0 0 0 0 0 0 0 0 0 0 0 0 0
salesMaturitiesOfInvestments 0 0 0 0 0 0 0 0 0 0 0 0 0 0
otherInvestingActivites -5M -887 000 -1M -486 000 -5M -21 000 0 0 -25 000
netCashUsedForInvestingActivites -5M -887 000 113 000 -905 000 -6M -649 000 -348 000 -677 000 -374 000
debtRepayment -250 000 -250 000 -251 000 -254 000 -31M -16 000 -16 000 -4000 -7000
commonStockIssued 0 0 0 0 766 000 386 000 20 000 0 0
commonStockRepurchased -83 000 -526 000 -3M -110 000 -349 000 -2M -10M 0 0 0 -1M 0 -5M -2M
dividendsPaid 0 0 0 0 0 0 0 0 0
otherFinancingActivites -524 000 -318 000 388 000 244 000 -1M 370 000 0 0 137 000
netCashUsedProvidedByFinancingActivities -857 000 -1M 27 000 -359 000 -32M 370 000 4000 -4000 130 000
effectOfForexChangesOnCash 0 0 0 0 0 0 0 0 -7M 0 0 0 0 0
netChangeInCash 23M 12M 22M 20M 21M -34M 16M 13M 7M -5M -21M 715 000 -9M 27M
cashAtEndOfPeriod 142M 119M 104M 89M 69M 48M 82M 81M 69M 61M 66M 73M 87M 96M
cashAtBeginningOfPeriod 119M 106M 82M 69M 48M 82M 66M 69M 61M 66M 87M 73M 96M 69M
operatingCashFlow 29M 14M 66M 22M 22M 5M 27M 13M 8M -4M -18M 959 000 -2M -30M
capitalExpenditure -4M 0 -2M 2M -419 000 -1M -2M -649 000 -348 000 -677 000 -2M -374 000 -3M -4M
freeCashFlow 25M 14M 65M 23M 21M 4M 25M 12M 7M -5M -19M 585 000 -5M -34M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-26 2024-02-28 2023-05-01 2022-02-28 2021-03-08
fiscalYear 2024 2023 2022 2021 2020
otherInvestingActivities 0 0 0 -177 000 -327 000
netCashProvidedByInvestingActivities -10M -2M -3M -3M -5M
netDebtIssuance -32M -52 000 -41 000 -38 000 -26M
longTermNetDebtIssuance -32M -52 000 -41 000 -38 000 -26M
shortTermNetDebtIssuance 0 0 0 0 0
netStockIssuance -3M -9M -539 000 -5M 98M
netCommonStockIssuance -3M -9M -539 000 -5M -2M
commonStockIssuance 0 997 000 651 000 0 0
netPreferredStockIssuance 0 0 0 0 100M
netDividendsPaid 0 0 0 0 0
commonDividendsPaid 0 0 0 0 0
preferredDividendsPaid 0 0 0 0 0
otherFinancingActivities 159 000 0 0 1M -10M
netCashProvidedByFinancingActivities -34M -9M -580 000 -3M 62M
incomeTaxesPaid 3M 0 0 169 000 208 000
interestPaid 3M 0 0 4M 7M

Earning call transcript

2025 q3
2025-10-29 ET (fiscal 2025 q3)
2025 q2
2025-07-30 ET (fiscal 2025 q2)
2025 q1
2025-04-30 ET (fiscal 2025 q1)
2024 q4
2025-02-26 ET (fiscal 2024 q4)
2024 q3
2024-10-30 ET (fiscal 2024 q3)
2024 q2
2024-07-31 ET (fiscal 2024 q2)
2024 q1
2024-04-30 ET (fiscal 2024 q1)
2023 q4
2024-02-28 ET (fiscal 2023 q4)
2023 q3
2023-10-30 ET (fiscal 2023 q3)
2023 q2
2023-08-01 ET (fiscal 2023 q2)
2023 q1
2023-05-02 ET (fiscal 2023 q1)
2022 q4
2023-02-28 ET (fiscal 2022 q4)
2022 q3
2022-11-02 ET (fiscal 2022 q3)
2022 q2
2022-08-03 ET (fiscal 2022 q2)
2022 q1
2022-05-04 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2026-11-06 ET
MIMEDX to Participate in Upcoming Investor Conferences
2026-10-28 ET
MIMEDX Announces Third Quarter 2026 Operating & Financial Results
2026-10-28 ET
MIMEDX Announces $25 Million Patent License Agreement
2026-10-14 ET
MIMEDX to Host Third Quarter 2026 Operating and Financial Results Conference Call on October 28, 2026
2026-09-23 ET
MIMEDX Announces Favorable Federal Court Ruling in AXIOFILL® Regulatory Classification Matter
2026-09-08 ET
MIMEDX to Participate in Upcoming Investor Conferences
2026-07-29 ET
MIMEDX Announces Second Quarter 2026 Operating & Financial Results
2026-07-20 ET
MIMEDX to Host Second Quarter 2026 Operating and Financial Results Conference Call on July 29
2026-05-21 12:45 ET
MIMEDX to Participate in Craig-Hallum 23rd Annual Institutional Investor Conference
2026-05-08 ET
MIMEDX Announces Launch of G4Derm® Plus
2026-04-29 ET
MIMEDX Announces First Quarter 2026 Operating & Financial Results
2026-04-22 ET
MIMEDX to Host First Quarter 2026 Operating and Financial Results Conference Call on April 29
2026-04-16 ET
MIMEDX Announces Restructuring and Cost Reduction Initiative
2026-04-02 ET
MIMEDX to Sponsor Leading Advanced Wound Care Conferences
2026-03-23 ET
MIMEDX Announces Launch of CHORIOFIX™
2026-03-05 ET
MIMEDX Expands Surgical Product Portfolio with the Launch of AMNIOFIX® Thyroid Shields
2026-02-25 ET
MIMEDX Announces Record Fourth Quarter and Full Year 2025 Operating and Financial Results
2026-02-17 13:00 ET
MIMEDX to Host Fourth Quarter and Full Year 2025 Operating and Financial Results Conference Call on February 25
2026-02-04 15:27 ET
MIMEDX Enters into Exclusive Distribution Agreement with Summit Products Group for Multiple Innovative Surgical & Wound Products
2026-02-02 13:00 ET
MIMEDX Celebrates 15 Year Anniversary of EPIFIX® and AMNIOFIX®
2025-12-22 ET
MIMEDX Enters into Exclusive U.S. Distribution Agreement for RegenKit®-Wound Gel
2025-12-19 ET
MIMEDX Announces Publication in the Journal of Inflammation Focused on Immunomodulatory Effects of Purion® Processed Human Amniotic Membrane Allografts In Vitro
2025-11-13 ET
MIMEDX Provides Update on EPIEFFECT® Randomized Controlled Trial
2025-11-10 ET
MIMEDX to Participate in Upcoming Investor Conferences
2025-11-03 ET
MIMEDX Comments on CY 2026 Medicare Physician Fee Schedule Final Rule
2025-10-29 20:01 ET
MIMEDX Announces Record Revenue for Third Quarter 2025
2025-10-15 ET
MIMEDX to Host Third Quarter 2025 Operating and Financial Results Conference Call on October 29
2025-10-06 ET
MIMEDX Announces Launch of EPIXPRESS®
2025-09-03 ET
MIMEDX to Sponsor and Attend Symposium on Advanced Wound Care (SAWC) Fall
2025-08-27 ET
MIMEDX to Participate in Upcoming Investor Conferences
2025-07-30 ET
MIMEDX Announces Record Second Quarter 2025 Operating and Financial Results
2025-07-30 ET
MIMEDX Announces Strategic Collaboration with Vaporox, Inc.
2025-07-16 ET
MIMEDX to Host Second Quarter 2025 Operating and Financial Results Conference Call on July 30
2025-07-15 ET
MIMEDX Comments on Proposed Medicare Reimbursement Rule Changes for CY 2026
2025-05-27 ET
MIMEDX to Participate in Upcoming Investor Conferences
2025-05-06 ET
MIMEDX to Present at the BofA Securities 2025 Healthcare Conference
2025-05-05 ET
MIMEDX Announces Publication of Health Economics Data in Mohs Micrographic Surgery (MMS)
2025-04-30 ET
MIMEDX Announces First Quarter 2025 Operating and Financial Results
2025-04-16 ET
MIMEDX to Host First Quarter 2025 Operating and Financial Results Conference Call on April 30
2025-04-10 ET
MIMEDX to Feature Growing Body of Clinical and Scientific Evidence at Upcoming Wound & Surgical-Focused Industry Conferences
2025-02-27 ET
MIMEDX to Present at TD Cowen 45th Annual Health Care Conference
2025-02-26 ET
MIMEDX Announces Fourth Quarter and Full Year 2024 Operating and Financial Results
2025-02-05 ET
MIMEDX to Host Fourth Quarter and Full Year 2024 Operating and Financial Results Conference Call on February 26
2024-12-17 ET
MIMEDX Files Patent Infringement Lawsuit Against Surgenex
2024-12-04 ET
MIMEDX to Participate in Upcoming Investor Conferences
2024-11-14 ET
MIMEDX’s Advocacy to Rein in Runaway Medicare Spend for Skin Substitutes Has Yielded Significant Results with Planned Implementation of LCDs
2024-11-04 ET
MIMEDX to Participate in Upcoming Investor Conferences
2024-10-30 20:01 ET
MIMEDX Announces Third Quarter 2024 Operating and Financial Results
2024-10-14 12:00 ET
MIMEDX to Host Third Quarter 2024 Operating and Financial Results Conference Call on October 30
2024-10-08 20:01 ET
MIMEDX Points to The New York Times Article on the Vast Benefits of Placental Tissue
2024-10-01 20:01 ET
MIMEDX Showcases Leading Allograft Portfolio and Its Latest Scientific and Clinical Evidence at SAWC Fall
2024-09-11 17:03 ET
EX-MiMEDX EMPLOYEES ALLEGE MiMEDX "PRESSURE[D] HEALTHCARE PROVIDERS TO TREAT WOUNDED VETERANS, DIABETICS, CHRONIC WOUND SUFFERERS, AND OTHER PATIENTS WITH MEDICALLY UNNECESSARY OR UNSUITABLE PRODUCTS"
2024-09-04 20:23 ET
THIRD DEFENDANT FIGHTS BACK AGAINST MiMEDX, CLAIMING 'DISREPUTABLE AND UNLAWFUL BUSINESS PRACTICES'
2024-08-27 12:00 ET
MIMEDX to Participate in Upcoming Investor Conferences
2024-07-31 20:02 ET
MIMEDX Announces Launch of HELIOGEN™ Fibrillar Collagen Matrix
2024-07-31 20:01 ET
MIMEDX Announces Second Quarter 2024 Operating and Financial Results
2024-07-22 12:10 ET
MIMEDX Announces Publication Focused on Surgical Applications Using MIMEDX Placental-Based Allografts in Nature – Scientific Reports
2024-07-17 12:00 ET
MIMEDX to Host Second Quarter 2024 Operating and Financial Results Conference Call on July 31
2024-06-26 20:01 ET
MIMEDX Announces the Appointment of Kim Moller to Chief Commercial Officer
2024-05-20 10:00 ET
4 Stocks to Watch in the Booming Regenerative Medicine Market
2024-05-15 12:00 ET
MIMEDX to Participate in Upcoming Investor Conferences
2024-04-30 20:01 ET
MIMEDX Announces First Quarter 2024 Operating and Financial Results
2024-04-16 12:00 ET
MIMEDX to Host First Quarter 2024 Operating and Financial Results Conference Call on April 30
2024-03-27 12:00 ET
MIMEDX Provides Update on AXIOFILL® Request for Designation (“RFD”) from FDA
2024-03-13 12:00 ET
MIMEDX Introduces E-Commerce and Account Management Platform
2024-03-04 13:00 ET
MIMEDX Announces Appointment of Two New Independent Directors
2024-02-28 21:01 ET
MIMEDX Announces Fourth Quarter and Full Year 2023 Operating and Financial Results
2024-02-20 13:00 ET
MIMEDX to Present at TD Cowen 44th Annual Health Care Conference
2024-02-12 13:00 ET
MIMEDX to Host Fourth Quarter and Full Year 2023 Operating and Financial Results Conference Call on February 28
2024-01-22 13:00 ET
MIMEDX Announces Improved Capital Structure with New Senior Secured Credit Facilities and Debt Refinancing
2023-12-29 22:00 ET
MIMEDX Provides AXIOFILL® Update & Reiterates 2023 Full Year Net Sales and Fourth Quarter Adjusted EBITDA Margin Outlook
2023-12-28 13:00 ET
MIMEDX Announces Conversion of Outstanding Series B Convertible Preferred Stock to Common Stock
2023-11-13 13:00 ET
MIMEDX to Participate in Upcoming Investor Conferences
2023-11-02 12:00 ET
MIMEDX to Highlight Published Data at SAWC Fall
2023-10-30 20:01 ET
MIMEDX Announces Third Quarter 2023 Operating and Financial Results
2023-10-16 12:00 ET
MIMEDX to Host Third Quarter 2023 Operating and Financial Results Conference Call on October 30
2023-09-26 12:00 ET
MIMEDX Announces Launch of EPIEFFECT™
2023-09-05 12:00 ET
MIMEDX to Present at Upcoming Investor Conferences
2023-08-15 20:01 ET
MediWound Announces Collaboration with MIMEDX on EscharEx® Phase III Study
2023-08-01 20:01 ET
MIMEDX Announces Second Quarter 2023 Operating and Financial Results
2023-07-18 12:00 ET
MIMEDX to Host Second Quarter 2023 Operating and Financial Results Conference Call on August 1
2023-07-11 12:30 ET
MIMEDX Announces Favorable Ruling in Putative Securities Class Action Case
2023-07-05 12:00 ET
MIMEDX Appoints Doug Rice as Chief Financial Officer
2023-06-20 20:01 ET
MIMEDX Announces Strategic Realignment: Increases Focus on Wound & Surgical Business, Expected to Significantly Improve Profitability
2023-06-20 ET
MIMEDX Announces Strategic Realignment: Increases Focus on Wound & Surgical Business, Expected to Significantly Improve Profitability
2023-05-02 20:01 ET
MIMEDX Announces First Quarter 2023 Operating and Financial Results
2023-04-18 12:00 ET
MIMEDX to Host First Quarter 2023 Operating and Financial Results Conference Call on May 2
2023-03-23 20:01 ET
MIMEDX Announces Chief Financial Officer Transition
2023-03-16 12:00 ET
MIMEDX Comments on Recent Data Brief Published by Office of Inspector General
2023-02-28 21:01 ET
MIMEDX Announces Fourth Quarter and Full Year 2022 Operating and Financial Results
2023-02-15 13:00 ET
MIMEDX to Host Fourth Quarter and Full Year 2022 Operating and Financial Results Conference Call on February 28
2023-01-30 13:00 ET
MIMEDX Appoints Joseph H. Capper as Chief Executive Officer and Director
2023-01-09 13:02 ET
MIMEDX Confirms Fourth Quarter and Full Year 2022 Net Sales Expectations, Comments on Evolving Medicare Reimbursement Landscape and Provides Corporate Updates
2023-01-04 21:01 ET
MIMEDX Announces Commercial Launch of EPIFIX® in Japan with Exclusive Distribution Agreement with GUNZE MEDICAL LIMITED
2023-01-03 13:00 ET
MIMEDX Appoints Ricci S. Whitlow as Chief Operating Officer
2022-12-08 13:00 ET
MIMEDX Announces Wound & Surgical Product Pipeline Expansion via In-Licensing and Distribution Agreement with Turn Therapeutics
2022-11-10 13:00 ET
MIMEDX to Present at Upcoming Investor Conferences
2022-11-02 20:15 ET
MIMEDX Announces Third Quarter 2022 Operating and Financial Results
2022-10-19 12:00 ET
MIMEDX to Host Third Quarter 2022 Operating and Financial Results Conference Call on November 2
2022-10-04 12:00 ET
MIMEDX Appoints Matt Notarianni as Head of Investor Relations
2022-09-20 12:00 ET
MIMEDX Announces Launch of AXIOFILL™
2022-09-19 11:00 ET
MIMEDX Announces Launch of AMNIOEFFECT™
2022-09-12 20:30 ET
MIMEDX EPIFIX® Receives Reimbursement Approval in Japan
2022-09-06 11:00 ET
MIMEDX Announces Leadership Transition
2022-08-26 13:00 ET
Regenerative Engineering Society Establishes Award in Honor of MIMEDX Board Member, Dr. Cato T. Laurencin
2022-08-04 20:07 ET
MIMEDX to Present at the Canaccord Genuity 42nd Annual Growth Conference
2022-08-02 20:05 ET
MIMEDX Announces Second Quarter 2022 Operating and Financial Results
2022-07-27 12:00 ET
MIMEDX Announces Formation of Regenerative Medicine Scientific Advisory Board Comprised of Renowned Industry and Academic Experts
2022-07-20 12:00 ET
MIMEDX to Host Second Quarter 2022 Operating and Financial Results Conference Call on August 3
2022-07-18 13:35 ET
MIMEDX Welcomes Kate Surdez as Chief Human Resources Officer
2022-06-15 12:30 ET
MIMEDX Engages Nordic Bioscience Clinical Development A/S to Propel Registrational Trials of Placental Biologic Injectable for Knee Osteoarthritis
2022-06-14 21:16 ET
Prescience Point Capital Management Says MiMedx Shareholders Have Spoken: Voiced Their Desire For Change
2022-06-14 ET
Prescience Point Capital Management Says MiMedx Shareholders Have Spoken: Voiced Their Desire For Change
2022-06-07 20:05 ET
MIMEDX Shareholders Vote to Approve All Proposals at the 2022 Annual Meeting
2022-06-07 18:42 ET
Prescience Point Capital Management Calls On MiMedx Group to Immediately Release Preliminary Voting Results of its Annual Meeting
2022-06-03 12:00 ET
MIMEDX Reminds Shareholders to Pre-Register for the Upcoming Virtual 2022 Annual Meeting of Shareholders
2022-06-02 12:03 ET
MIMEDX Addresses Presentation by Prescience Point
2022-05-31 20:05 ET
MIMEDX Board Chair Dr. M. Kathleen Behrens Writes Letter to Fellow Shareholders
2022-05-31 18:05 ET
Prescience Point Capital Management Releases Presentation Detailing Board And Management Failures at MiMedx Group
2022-05-31 12:00 ET
MIMEDX Receives $4.6 Million Award from the Department of Defense to Advance the Treatment of Combat Casualty Wounds and Burns
2022-05-25 21:26 ET
Leading Independent Proxy Advisory Firm ISS Recommends that MIMEDX Shareholders Vote “FOR ALL” of the Company’s Proposals
2022-05-20 13:00 ET
Leading Independent Proxy Advisory Firm Glass Lewis Recommends that MIMEDX Shareholders Vote “FOR ALL” of the Company’s Proposals
2022-05-18 20:18 ET
MIMEDX Investor Presentation Highlights Clear Strategy for Value Creation
2022-05-18 12:55 ET
Prescience Point Capital Management Calls on MiMedx to Confirm the Company Has Received Letters of Serious Concern from other Shareholders
2022-05-16 12:00 ET
MIMEDX Mails Letter to Shareholders
2022-05-09 12:00 ET
MIMEDX Comments on Prescience Point’s False and Misleading Statements
2022-05-06 13:12 ET
Prescience Point Capital Management Issues Open Letter to Shareholders of MiMedx Group
2022-05-05 12:00 ET
MIMEDX to Participate at Upcoming Investor Conferences
2022-05-03 20:31 ET
MIMEDX Announces First Quarter 2022 Operating and Financial Results
2022-04-29 13:09 ET
MIMEDX Comments on Prescience Point’s Recent Filing
2022-04-20 12:00 ET
MIMEDX to Host First Quarter 2022 Operating and Financial Results Conference Call on May 4
2022-04-05 12:00 ET
MIMEDX to Present Health Economics Clinical Data for EPIFIX® in Treatment of Lower Extremity Diabetic Ulcers at SAWC Spring
2022-03-16 12:05 ET
WoundGenex Partners with MIMEDX to Launch Premier Graft Program to Wound Care Providers Nationwide
2022-03-15 12:00 ET
MIMEDX to Present at the Canaccord Genuity Musculoskeletal Conference
2022-02-28 21:06 ET
MIMEDX Announces Fourth Quarter and Full Year 2021 Operating and Financial Results
2022-02-16 13:35 ET
Peer-Reviewed Study Demonstrates Increased Cost-Effectiveness of MIMEDX Dehydrated Human Amnion Chorion Membrane (DHACM) in Lower Extremity Diabetic Ulcer (LEDU) Treatment Compared to Standard of Care
2022-02-14 13:00 ET
MIMEDX to Host Fourth Quarter 2021 Operating and Financial Results Conference Call on February 28
2022-01-10 13:00 ET
MIMEDX Outlines Key Strategic Milestones for 2022
2022-01-04 21:05 ET
MIMEDX to Participate at the H.C. Wainwright BioConnect Virtual Conference
2021-12-22 13:00 ET
MIMEDX to Present at the 40th Annual J.P. Morgan Healthcare Conference
2021-12-07 12:00 ET
MIMEDX Outlines Long-Term Value Creation Strategy at Virtual Investor Day
2021-11-30 13:00 ET
MIMEDX Announces Speakers for December 7 Investor Day
2021-11-22 13:00 ET
MIMEDX to Present at the Piper Sandler 33rd Annual Healthcare Conference
2021-11-17 13:00 ET
Peer Reviewed Study Demonstrates MIMEDX Dehydrated Human Amnion Chorion Membrane (dHACM) Outperforms Standard of Care in Select Mohs Defect Reconstructions
2021-11-02 20:50 ET
MIMEDX Announces Third Quarter 2021 Operating and Financial Results
2021-11-02 12:00 ET
MIMEDX to Participate at Upcoming Investor Conferences
2021-11-01 12:30 ET
Two New Studies Demonstrate in vitro Bioactivity Potential of Micronized Dehydrated Human Amnion Chorion Membrane (mdHACM) to Prevent Pathological Processes Underlying Osteoarthritis (OA) and Tendinopathy
2021-10-20 12:00 ET
MIMEDX to Host Third Quarter 2021 Operating and Financial Results Conference Call on November 3
2021-10-14 20:05 ET
MIMEDX to Host Virtual Investor Day on December 7, 2021
2021-10-13 11:00 ET
Net Health Agreement with MIMEDX Streamlines Complex Insurance Benefits Verifications
2021-09-13 10:30 ET
MIMEDX Reports Top-line Data from Two Late-Stage Musculoskeletal Trials with Proprietary Amniotic Tissue Technology
2021-09-08 11:30 ET
MIMEDX Announces Effectiveness of Shelf Registration Statement
2021-09-07 12:00 ET
MIMEDX to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
2021-08-27 13:00 ET
MIMEDX Announces Filing of Shelf Registration Statement with Securities and Exchange Commission
2021-08-17 12:30 ET
Medicare Data: Significant Reductions in Amputations, Emergency Visits, and Hospital Readmissions Associated with Advanced Treatment Using Skin Substitute Products for Lower Extremity Diabetic Ulcers (LEDUs)
2021-08-12 12:30 ET
MIMEDX Promotes Marion Snyder to Chief of Staff, Senior Vice President, Government Affairs
2021-08-03 21:22 ET
MIMEDX Announces Second Quarter 2021 Operating and Financial Results
2021-07-20 12:00 ET
MIMEDX to Host Second Quarter 2021 Operating and Financial Results Conference Call on August 4
2021-07-14 13:00 ET
NAACP to Present Historic Spingarn Medal to Regenerative Engineering Pioneer Cato T. Laurencin, M.D., Ph.D., at 112th Annual Convention
2021-06-28 12:00 ET
MIMEDX Joins Russell 3000® and 2000® Indexes
2021-06-16 12:00 ET
MIMEDX to Present at the Raymond James 2021 Human Health Innovation Conference
2021-06-15 20:54 ET
New Study Demonstrates Potential for MIMEDX Purion® Processed Dehydrated Human Amnion/Chorion Membrane to Modulate Pathological Scar Tissue Formation
2021-06-08 12:30 ET
MIMEDX Receives Regulatory Approval to Commercialize EPIFIX® in Japan
2021-05-27 12:00 ET
MIMEDX to Participate at the Jefferies Virtual Healthcare Conference
2021-05-25 12:30 ET
MIMEDX Reminds Shareholders to Pre-Register for the Upcoming Virtual 2021 Annual Meeting of Shareholders
2021-05-12 12:00 ET
MIMEDX Reminds Shareholders to Vote at the Upcoming Annual Meeting
2021-05-10 12:00 ET
MIMEDX to Participate at Upcoming Investor Conferences
2021-05-06 12:00 ET
MIMEDX Announces Collaborative Agreement with the Wake Forest Institute for Regenerative Medicine
2021-05-04 20:03 ET
Prescience Point Announces Withdrawal of Its Slate of Nominees to MiMedx's Board
2021-05-04 13:15 ET
MIMEDX Urges Shareholders to Consider Prescience Point’s Motivations Before Voting Their Shares at the Company’s Annual Meeting
2021-05-03 12:02 ET
MIMEDX Files Definitive Proxy Materials and Mails Letter to Shareholders Highlighting Actions Taken to Transform MIMEDX and Drive Significant Value for Shareholders
2021-04-28 21:00 ET
MiMedx Announces First Quarter 2021 Financial and Operating Results
2021-04-28 14:21 ET
MiMedx Welcomes Dirk Stevens, Ph.D., as Senior Vice President, Quality Assurance and Regulatory Affairs
2021-04-22 12:00 ET
MiMedx to Host First Quarter 2021 Operating and Financial Results Conference Call on April 29
2021-04-19 13:00 ET
MiMedx Announces Last Patients Last Visits in Three Late-Stage Musculoskeletal Trials with Proprietary Tissue Technology
2021-04-16 16:06 ET
MiMedx Confirms Receipt of Director Nominations from Prescience Point Capital Management
2021-04-16 11:30 ET
Prescience Point Capital Management to Nominate Four Highly Qualified Director Candidates to MiMedx Board at 2021 Annual Meeting
2021-03-30 12:00 ET
MiMedx Awarded Amniotic Tissue Supplier Agreement with Premier® Inc.’s SURPASS™ Purchasing Program
2021-03-08 22:33 ET
MiMedx Announces Appointment of Phyllis Gardner, M.D. to Board of Directors
2021-03-08 22:32 ET
MiMedx Announces Fourth Quarter and Full Year 2020 Financial and Operating Results
2021-03-03 13:00 ET
MiMedx to Participate at Upcoming Investor Conferences
2021-03-02 13:00 ET
MiMedx to Host Fourth Quarter and Full Year 2020 Operating and Financial Results Conference Call on March 9
2021-02-10 13:00 ET
MiMedx to Participate at the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
2021-01-06 13:00 ET
Reminder: MiMedx to Present at the 39th Annual J.P. Morgan Healthcare Conference
2021-01-04 13:00 ET
MiMedx to Participate at the H.C. Wainwright BioConnect 2021 Conference
2020-12-16 14:14 ET
Prescience Point Capital Management Raises Price Target on MiMedx Group to $31 Per Share
2020-12-07 13:00 ET
MiMedx to Present at the 39th Annual J.P. Morgan Healthcare Conference
2020-12-01 14:22 ET
MiMedx Appoints Jack Howarth as Senior Vice President, Investor Relations
2020-11-24 22:15 ET
MiMedx To Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference
2020-11-13 13:00 ET
MiMedx To Host Virtual 2020 Annual Meeting of Shareholders on Friday, November 20
2020-11-12 13:00 ET
MiMedx To Present At Canaccord Genuity Virtual MedTech & Diagnostics Forum
2020-11-04 21:07 ET
MiMedx Announces Third Quarter 2020 Financial Results
2020-11-04 13:00 ET
MiMedx To Advance the Conversation of Study Bias in the Clinical Evaluation of Skin Substitutes in Chronic Wounds at SAWC FALL
2020-11-03 22:30 ET
MiMedx Shares to Commence Trading on Nasdaq on Wednesday, November 4, 2020
2020-11-03 13:00 ET
MiMedx Announces Largest U.S. Commercial Payor Will Provide Coverage for EpiFix in the Treatment of Diabetic Foot Ulcers
2020-10-30 20:52 ET
MiMedx Announces Relisting on Nasdaq
2020-10-29 20:05 ET
MiMedx to Host Third Quarter 2020 Financial Results Call on November 5
2020-10-15 12:23 ET
MiMedx Files Definitive Proxy Materials
2020-09-21 12:30 ET
MiMedx Concludes Enrollment for Phase 2B Study of Osteoarthritis (OA) of the Knee
2020-09-21 10:15 ET
MiMedx Announces Preliminary Third Quarter 2020 Net Sales
2020-09-17 15:00 ET
MiMedx Concludes Enrollment for Phase 3 Plantar Fasciitis Trial
2020-09-14 12:00 ET
MiMedx Launches EpiCord Expandable Placental Allograft as Addition to Market Leading Portfolio
2020-08-24 13:00 ET
MiMedx to Discuss Strategic Priorities at Upcoming Virtual 2019 Annual Meeting of Shareholders
2020-08-10 13:00 ET
MiMedx Welcomes Robert B. Stein, M.D., Ph.D., to Head Revitalized R&D Efforts
2020-08-04 21:21 ET
MiMedx Files Second Quarter 2020 Form 10-Q
2020-08-03 12:06 ET
MiMedx Files Definitive Proxy Materials
2020-07-28 11:30 ET
MiMedx Adds Rohit Kashyap, Ph.D., to Leadership Team as Executive Vice President and Chief Commercial Officer
2020-07-06 10:45 ET
MiMedx Announces Filing of 2020 First Quarter Form 10-Q
2020-07-06 10:00 ET
MiMedx Announces Filing of 2019 Annual Report
2020-07-02 13:00 ET
MiMedx Announces Concurrent $150 Million Private Equity and Debt Financings
2020-05-08 23:26 ET
MiMedx Provides Update on Payment Protection Program Loan
2020-05-05 20:30 ET
MiMedx Announces Appointment of William L. Phelan as Chief Accounting Officer
2020-04-21 14:18 ET
MiMedx Announces Additional Access to Capital and Financing
2020-04-06 16:27 ET
MiMedx Announces Settlement of VA Pricing Investigation
2020-03-19 10:06 ET
MiMedx Names Peter M. Carlson as Chief Financial Officer
2020-03-17 21:43 ET
MiMedx Announces Filing of 2018 Annual Report
2019-12-16 13:30 ET
MiMedx Announces Addition of Peter M. Carlson
2019-12-12 21:15 ET
MiMedx Provides Update Regarding Timing of Restatement
2019-11-26 17:49 ET
MiMedx Announces Securities and Exchange Commission Settlement
2019-11-26 13:30 ET
MiMedx Names William "Butch" Hulse as General Counsel and Secretary

SEC forms

Show financial reports only

SEC form 10
2026-10-28 00:00 ET
MiMedx Group reported for 2026 q3
SEC form 8
2026-10-28 00:00 ET
MiMedx Group published news for 2026 q3
SEC form 8
2026-10-28 00:00 ET
MiMedx Group published news for 2026 q3
SEC form 8
2026-10-28 00:00 ET
MiMedx Group published news for 2026 q3
SEC form 8
2026-10-28 00:00 ET
MiMedx Group published news for 2026 q3
SEC form 8
2026-08-11 20:44 ET
MiMedx Group published news for 2026 q2
SEC form 8
2026-07-29 20:08 ET
MiMedx Group published news for 2026 q2
SEC form 8
2026-07-29 20:08 ET
MiMedx Group published news for 2026 q2
SEC form 8
2026-07-29 20:08 ET
MiMedx Group published news for 2026 q2
SEC form 8
2026-07-29 20:08 ET
MiMedx Group published news for 2026 q2
SEC form 10
2026-07-29 20:06 ET
MiMedx Group reported for 2026 q2
SEC form 8
2026-07-29 20:03 ET
MiMedx Group published news for 2026 q2
SEC form 8
2026-07-29 20:03 ET
MiMedx Group published news for 2026 q2
SEC form 8
2026-07-29 20:03 ET
MiMedx Group published news for 2026 q2
SEC form 8
2026-07-29 20:03 ET
MiMedx Group published news for 2026 q2
SEC form 8
2026-07-29 20:03 ET
MiMedx Group published news for 2026 q2
SEC form 8
2026-04-29 20:01 ET
MiMedx Group published news for 2026 q1
SEC form 8
2026-04-29 20:01 ET
MiMedx Group published news for 2026 q1
SEC form 8
2026-04-29 20:01 ET
MiMedx Group published news for 2026 q1
SEC form 8
2026-04-29 20:01 ET
MiMedx Group published news for 2026 q1
SEC form 10
2026-04-29 20:00 ET
MiMedx Group reported for 2026 q1
SEC form 8
2026-02-25 16:02 ET
MiMedx Group published news for 2025 q4
SEC form 8
2026-02-25 16:02 ET
MiMedx Group published news for 2025 q4
SEC form 8
2026-02-25 16:02 ET
MiMedx Group published news for 2025 q4
SEC form 8
2026-02-25 16:02 ET
MiMedx Group published news for 2025 q4
SEC form 10
2026-02-25 16:01 ET
MiMedx Group reported for 2025 q4
SEC form 8
2026-01-12 13:04 ET
MiMedx Group published news for 2025 q4
SEC form 8
2026-01-12 13:04 ET
MiMedx Group published news for 2025 q4
SEC form 8
2025-10-29 20:07 ET
MiMedx Group published news for 2025 q3
SEC form 8
2025-10-29 20:07 ET
MiMedx Group published news for 2025 q3
SEC form 8
2025-10-29 20:07 ET
MiMedx Group published news for 2025 q3
SEC form 8
2025-10-29 20:07 ET
MiMedx Group published news for 2025 q3
SEC form 10
2025-10-29 20:00 ET
MiMedx Group reported for 2025 q3
SEC form 8
2025-07-30 20:03 ET
MiMedx Group published news for 2025 q2
SEC form 8
2025-07-30 20:03 ET
MiMedx Group published news for 2025 q2
SEC form 8
2025-07-30 20:03 ET
MiMedx Group published news for 2025 q2
SEC form 8
2025-07-30 20:03 ET
MiMedx Group published news for 2025 q2
SEC form 10
2025-07-30 20:01 ET
MiMedx Group reported for 2025 q2
SEC form 10
2025-04-30 00:00 ET
MiMedx Group reported for 2025 q1
SEC form 8
2025-04-30 00:00 ET
MiMedx Group published news for 2025 q1
SEC form 8
2025-04-30 00:00 ET
MiMedx Group published news for 2025 q1
SEC form 8
2025-04-30 00:00 ET
MiMedx Group published news for 2025 q1
SEC form 8
2025-04-30 00:00 ET
MiMedx Group published news for 2025 q1
SEC form 10
2025-02-26 00:00 ET
MiMedx Group reported for 2024 q4
SEC form 8
2025-02-26 00:00 ET
MiMedx Group published news for 2024 q4
SEC form 8
2025-02-26 00:00 ET
MiMedx Group published news for 2024 q4
SEC form 8
2025-02-26 00:00 ET
MiMedx Group published news for 2024 q4
SEC form 8
2024-10-30 16:56 ET
MiMedx Group published news for 2024 q3
SEC form 8
2024-10-30 16:56 ET
MiMedx Group published news for 2024 q3
SEC form 8
2024-10-30 16:56 ET
MiMedx Group published news for 2024 q3
SEC form 8
2024-10-30 16:56 ET
MiMedx Group published news for 2024 q3
SEC form 10
2024-10-30 16:01 ET
MiMedx Group reported for 2024 q3
SEC form 10
2024-10-30 00:00 ET
MiMedx Group published news for 2024 q3
SEC form 8
2024-07-31 16:11 ET
MiMedx Group published news for 2024 q2
SEC form 8
2024-07-31 16:11 ET
MiMedx Group published news for 2024 q2
SEC form 8
2024-07-31 16:11 ET
MiMedx Group published news for 2024 q2
SEC form 8
2024-07-31 16:11 ET
MiMedx Group published news for 2024 q2
SEC form 10
2024-07-31 16:00 ET
MiMedx Group reported for 2024 q2
SEC form 10
2024-07-31 00:00 ET
MiMedx Group published news for 2024 q2
SEC form 8
2024-04-30 16:10 ET
MiMedx Group published news for 2024 q1
SEC form 8
2024-04-30 16:10 ET
MiMedx Group published news for 2024 q1
SEC form 8
2024-04-30 16:10 ET
MiMedx Group published news for 2024 q1
SEC form 8
2024-04-30 16:10 ET
MiMedx Group published news for 2024 q1
SEC form 10
2024-04-30 16:04 ET
MiMedx Group reported for 2024 q1
SEC form 10
2024-04-30 00:00 ET
MiMedx Group published news for 2024 q1
SEC form 8
2024-02-28 16:22 ET
MiMedx Group published news for 2023 q4
SEC form 8
2024-02-28 16:22 ET
MiMedx Group published news for 2023 q4
SEC form 8
2024-02-28 16:22 ET
MiMedx Group published news for 2023 q4
SEC form 10
2024-02-28 16:02 ET
MiMedx Group reported for 2023 q4
SEC form 10
2024-02-28 00:00 ET
MiMedx Group published news for 2023 q4
SEC form 10
2023-10-30 16:07 ET
MiMedx Group reported for 2023 q3
SEC form 8
2023-10-30 16:05 ET
MiMedx Group published news for 2023 q3
SEC form 10
2023-10-30 00:00 ET
MiMedx Group published news for 2023 q3
SEC form 10
2023-08-01 16:04 ET
MiMedx Group reported for 2023 q2
SEC form 6
2023-08-01 16:03 ET
MiMedx Group published news for 2023 q2
SEC form 8
2023-08-01 00:00 ET
MiMedx Group published news for 2023 q2
SEC form 6
2023-07-06 18:12 ET
MiMedx Group published news for 2023 q2
SEC form 6
2023-07-05 09:02 ET
MiMedx Group published news for 2023 q2
SEC form 6
2023-06-20 16:03 ET
MiMedx Group published news for 2023 q1
SEC form 6
2023-06-14 16:23 ET
MiMedx Group published news for 2023 q1
SEC form 10
2023-05-02 00:00 ET
MiMedx Group published news for 2023 q1
SEC form 8
2023-05-02 00:00 ET
MiMedx Group published news for 2023 q1
SEC form 6
2023-03-24 16:17 ET
MiMedx Group published news for 2022 q4
SEC form 6
2023-03-15 18:07 ET
MiMedx Group published news for 2022 q4
SEC form 6
2023-02-28 16:08 ET
MiMedx Group published news for 2022 q4
SEC form 10
2023-02-28 16:01 ET
MiMedx Group reported for 2022 q4
SEC form 10
2023-02-28 00:00 ET
MiMedx Group reported for 2022 q4
SEC form 8
2023-02-28 00:00 ET
MiMedx Group reported for 2022 q4
SEC form 6
2023-02-23 17:27 ET
MiMedx Group published news for 2022 q4
SEC form 6
2023-01-31 17:31 ET
MiMedx Group published news for 2022 q4
SEC form 6
2023-01-30 08:14 ET
MiMedx Group published news for 2022 q4
SEC form 6
2023-01-09 08:12 ET
MiMedx Group published news for 2022 q4
SEC form 8
2023-01-09 00:00 ET
MiMedx Group published news for 2022 q4
SEC form 6
2023-01-03 17:26 ET
MiMedx Group published news for 2022 q4
SEC form 6
2022-12-16 16:18 ET
MiMedx Group published news for 2022 q3
SEC form 6
2022-12-08 08:14 ET
MiMedx Group published news for 2022 q3
SEC form 6
2022-11-30 07:00 ET
MiMedx Group published news for 2022 q3
SEC form 6
2022-11-17 08:01 ET
MiMedx Group published news for 2022 q3
SEC form 6
2022-11-02 16:22 ET
MiMedx Group published news for 2022 q3
SEC form 10
2022-11-02 16:15 ET
MiMedx Group reported for 2022 q3
SEC form 10
2022-11-02 00:00 ET
MiMedx Group reported for 2022 q3
SEC form 8
2022-11-02 00:00 ET
MiMedx Group reported for 2022 q3
SEC form 6
2022-09-16 17:01 ET
MiMedx Group published news for 2022 q2
SEC form 6
2022-09-06 07:03 ET
MiMedx Group published news for 2022 q2
SEC form 6
2022-08-10 09:13 ET
MiMedx Group published news for 2022 q2
SEC form 6
2022-08-02 16:09 ET
MiMedx Group published news for 2022 q2
SEC form 10
2022-08-02 16:02 ET
MiMedx Group reported for 2022 q2
SEC form 10
2022-08-02 00:00 ET
MiMedx Group reported for 2022 q2
SEC form 8
2022-08-02 00:00 ET
MiMedx Group reported for 2022 q2
SEC form 6
2022-06-30 16:38 ET
MiMedx Group published news for 2022 q1
SEC form 6
2022-06-13 17:26 ET
MiMedx Group published news for 2022 q1
SEC form 6
2022-05-24 08:11 ET
MiMedx Group published news for 2022 q1
SEC form 6
2022-05-10 09:26 ET
MiMedx Group published news for 2022 q1
SEC form 6
2022-05-03 16:37 ET
MiMedx Group published news for 2022 q1
SEC form 10
2022-05-03 16:26 ET
MiMedx Group reported for 2022 q1
SEC form 10
2022-05-03 00:00 ET
MiMedx Group reported for 2022 q1
SEC form 8
2022-05-03 00:00 ET
MiMedx Group reported for 2022 q1
SEC form 6
2022-04-29 09:13 ET
MiMedx Group published news for 2022 q1
SEC form 6
2022-04-26 16:05 ET
MiMedx Group published news for 2022 q1
SEC form 6
2022-03-22 08:00 ET
MiMedx Group published news for 2021 q4
SEC form 10
2022-02-28 17:11 ET
MiMedx Group published news for 2021 q4
SEC form 6
2022-02-28 16:10 ET
MiMedx Group published news for 2021 q4
SEC form 10
2022-02-28 00:00 ET
MiMedx Group published news for 2021 q4
SEC form 8
2022-02-28 00:00 ET
MiMedx Group published news for 2021 q4
SEC form 6
2022-01-10 08:05 ET
MiMedx Group published news for 2021 q4
SEC form 8
2022-01-10 00:00 ET
MiMedx Group published news for 2021 q4
SEC form 6
2021-12-07 12:45 ET
MiMedx Group published news for 2021 q3
SEC form 6
2021-11-22 08:01 ET
MiMedx Group published news for 2021 q3
SEC form 6
2021-11-02 16:53 ET
MiMedx Group published news for 2021 q3
SEC form 10
2021-11-02 16:45 ET
MiMedx Group published news for 2021 q3
SEC form 10
2021-11-02 00:00 ET
MiMedx Group published news for 2021 q3
SEC form 8
2021-11-02 00:00 ET
MiMedx Group published news for 2021 q3
SEC form 6
2021-09-13 06:33 ET
MiMedx Group published news for 2021 q2
SEC form 6
2021-08-03 17:26 ET
MiMedx Group published news for 2021 q2
SEC form 10
2021-08-03 17:14 ET
MiMedx Group published news for 2021 q2
SEC form 10
2021-08-03 00:00 ET
MiMedx Group published news for 2021 q2
SEC form 8
2021-08-03 00:00 ET
MiMedx Group published news for 2021 q2
SEC form 6
2021-07-07 16:05 ET
MiMedx Group published news for 2021 q2
SEC form 6
2021-06-23 08:33 ET
MiMedx Group published news for 2021 q1
SEC form 8
2021-06-23 00:00 ET
MiMedx Group published news for 2021 q1
SEC form 6
2021-06-10 16:19 ET
MiMedx Group published news for 2021 q1
SEC form 6
2021-06-03 16:56 ET
MiMedx Group published news for 2021 q1
SEC form 6
2021-05-25 08:31 ET
MiMedx Group published news for 2021 q1
SEC form 6
2021-05-12 08:20 ET
MiMedx Group published news for 2021 q1
SEC form 6
2021-05-03 08:00 ET
MiMedx Group published news for 2021 q1
SEC form 6
2021-04-29 16:30 ET
MiMedx Group published news for 2021 q1
SEC form 6
2021-04-28 17:09 ET
MiMedx Group published news for 2021 q1
SEC form 10
2021-04-28 16:14 ET
MiMedx Group published news for 2021 q1
SEC form 10
2021-04-28 00:00 ET
MiMedx Group published news for 2021 q1
SEC form 8
2021-04-28 00:00 ET
MiMedx Group published news for 2021 q1
SEC form 6
2021-04-21 08:30 ET
MiMedx Group published news for 2021 q1
SEC form 6
2021-04-19 09:00 ET
MiMedx Group published news for 2021 q1
SEC form 6
2021-04-05 16:18 ET
MiMedx Group published news for 2021 q1
SEC form 6
2021-03-30 17:22 ET
MiMedx Group published news for 2020 q4
SEC form 6
2021-03-10 09:26 ET
MiMedx Group published news for 2020 q4
SEC form 6
2021-03-08 17:39 ET
MiMedx Group published news for 2020 q4
SEC form 10
2021-03-08 17:27 ET
MiMedx Group published news for 2020 q4
SEC form 6
2021-01-08 21:21 ET
MiMedx Group published news for 2020 q4
SEC form 6
2020-12-18 18:35 ET
MiMedx Group published news for 2020 q3
SEC form 6
2020-12-09 16:42 ET
MiMedx Group published news for 2020 q3
SEC form 6
2020-11-30 16:21 ET
MiMedx Group published news for 2020 q3
SEC form 6
2020-11-27 16:07 ET
MiMedx Group published news for 2020 q3
SEC form 6
2020-11-19 21:13 ET
MiMedx Group published news for 2020 q3
SEC form 6
2020-11-19 06:08 ET
MiMedx Group published news for 2020 q3
SEC form 6
2020-11-04 16:14 ET
MiMedx Group published news for 2020 q3
SEC form 10
2020-11-04 16:04 ET
MiMedx Group published news for 2020 q3
SEC form 6
2020-10-30 17:28 ET
MiMedx Group published news for 2020 q3
SEC form 6
2020-10-22 09:07 ET
MiMedx Group published news for 2020 q3
SEC form 6
2020-10-15 09:28 ET
MiMedx Group published news for 2020 q3
SEC form 6
2020-10-05 16:04 ET
MiMedx Group published news for 2020 q3
SEC form 6
2020-10-05 08:34 ET
MiMedx Group published news for 2020 q3